Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study)

Annals of the Rheumatic Diseases
Yuko KanekoSURPRISE study group

Abstract

To evaluate the sustained remission and low disease activity after discontinuation of tocilizumab in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate. The SURPRISE study was a 2-year, open-label randomised controlled study. Among patients who had been randomised to additional tocilizumab (ADD-ON) or switch to tocilizumab (SWITCH) in the first year, those who achieved remission based on the disease activity score for 28 joints (DAS28-ESR<2.6) discontinued tocilizumab at week 52 and were observed for the following 52 weeks. The endpoint of the second year included tocilizumab-free remission and low disease-activity rates, functional outcome, radiological outcomes assessed with the modified total Sharp score (mTSS) and safety. The efficacy of reinstituted tocilizumab/methotrexate was also evaluated. A total of 105 patients who achieved remission at week 52 discontinued tocilizumab; 51 in ADD-ON continued methotrexate and 54 in SWITCH received no disease-modifying antirheumatic drugs. Sustained DAS28 low disease-activity rates were significantly higher in ADD-ON than in SWITCH (55%vs27%, p=0.005). Sustained remission rates at week 104 were 24% for ADD-ON and 14% for SWIT...Continue Reading

References

Apr 14, 2009·Joint, Bone, Spine : Revue Du Rhumatisme·Olivier BrocqLiana Euller-Ziegler
Mar 11, 2010·Annals of the Rheumatic Diseases·Josef S SmolenUNKNOWN T2T Expert Committee
Apr 28, 2010·Annals of the Rheumatic Diseases·Benazir SaleemPaul Emery
Jun 5, 2013·The Journal of Rheumatology·Luis Aguilar-LozanoCesar Ramos-Remus
Jun 5, 2016·Annals of the Rheumatic Diseases·Georg SchettRonald van Vollenhoven
Oct 30, 2016·Arthritis Research & Therapy·Elena NikiphorouLaure Gossec
Oct 13, 2017·Proceedings of the Japan Academy. Series B, Physical and Biological Sciences·Tsutomu Takeuchi

❮ Previous
Next ❯

Citations

Nov 15, 2018·Modern Rheumatology·Atsushi OgataKazuyuki Yoshizaki
May 16, 2019·Expert Opinion on Drug Delivery·Atsushi OgataKeiji Maeda
Apr 3, 2020·Frontiers of Medicine·Min ZhouJieming Qu
Sep 6, 2019·Clinical Rheumatology·Carmen Tze Kwan HoUNKNOWN Hong Kong Society of Rheumatology
Sep 24, 2020·Annals of Hematology·Mitsuhiro AkiyamaTsutomu Takeuchi
Apr 25, 2020·Nature Reviews. Rheumatology·Ernest H ChoyTadamitsu Kishimoto
Oct 18, 2018·Therapeutic Advances in Musculoskeletal Disease·Graeme Jones, Elena Panova
Oct 22, 2020·Future Microbiology·Gonzalo Segrelles-CalvoSusana Frases
Dec 8, 2020·Multidisciplinary Respiratory Medicine·Francesco MenzellaNicola Cosimo Facciolongo

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01120366

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.